Correction of the murine Wiskott-Aldrich syndrome phenotype by hematopoietic stem cell transplantation.
Allogeneic hematopoietic stem cell transplantation (HSCT) corrects the Wiskott-Aldrich syndrome (WAS) phenotype. However, the toxicity and mortality frequently associated with this approach warrant the exploration of new therapeutic strategies. Transplantation studies of a murine model of WAS deficiency have been limited by the occurrence of a radiation-induced fatal exacerbation of a pre-existing colitis in the peritransplantation period. Here we demonstrate that when crossed to a C57/B6 background, WAS-deficient males show little if any colitis and reliably survive HSCT. We show that HSCT corrects the hematologic and functional deficiencies of WAS knockout mice. These results strengthen the analogy between murine and human WAS and provide a basis for the use of WAS-deficient mice to explore novel approaches for correction of the disease phenotype.
Strom
Ted S
TS
Division of Experimental Hematology, Department of Hematology/Oncology, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
Li
Xiuling
X
Cunningham
John M
JM
Nienhuis
Arthur W
AW
D000818:Animals; D003092:Colitis / Q000175:diagnosis / Q000382:microbiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods / Q000592:standards; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D010641:Phenotype; D015996:Survival Rate; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000379:methods / Q000592:standards; D014923:Wiskott-Aldrich Syndrome / Q000150:complications / Q000382:microbiology / Q000628:therapy*